Claims

1. A method of inhibiting fungal growth in a host comprising administering to said host an acceptable carrier and an effective amount of a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d and 1e, wherein the structures of said formulae are as follows:



1a, Dolastatin 10
(Dov-Val-Dil-Dap-Doe)

;



1b, Dov-Val-Dil-Dap-Phe-3-[(5-phenyl)-1,4-thiadiazolamide]

;



1c, Dov-Val-Dil-Dap-Phe-3-[(5-thiomethyl)-1,4-thiadiazolamide]

;



1d, Dov-Val-Dil-Dap-Phe-OMe



1e, Dov-Val-Dil-Dap-Met-3-quinolylamide

2. The method according to claim 1 in which said fungi are *Cryptococcus neoformans*.

3. The method according to claim 1 in which said fungi induced infections are cryptococcosis and epidermal and systemic infections resulting from contact with *Cryptococcus neoformans*.

4. The method according to claim 9 in which said active ingredient is administered to said host by parenteral means.

5. The method according to claim 9 in which said active ingredient is administered topically to said host.

6. The method according to claim 9 in which said active ingredient is administered intravenously to said host.

7. The method according to claim 9 in which said active ingredient is administered in a suppository inserted in said host.

8. The method according to claim 5 in which said carrier comprises a water-and-oil emulsion, petrolatum mineral oil, a moisturizer, a solubilizer and fragrance.

9. The method according to claim 3 wherein said host is a mammal.

10. The method according to claim 9 in which said mammal is a human.

11. The method according to claim 10 in which said active ingredient is administered to said host by parenteral means.

12. The method according to claim 10 in which said active ingredient is administered topically to said host.

13. The method according to claim 10 in which said active ingredient is administered intravenously to said host.

14. The method according to claim 10 in which said active ingredient is administered in a suppository inserted in said host.

15. The method according to claim 12 in which said carrier comprises a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, a solubilizer and fragrance.